New LaunchApr 8, 2026, 09:11 AM
iBio Initiates First-in-Human Clinical Trial for IBIO-600 in Australia, Dosing Expected Q2 2026
AI Summary
iBio, Inc. has announced the initiation of a first-in-human clinical trial for its drug candidate, IBIO-600, in Australia. The company received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, paving the way for the trial. This marks a significant step forward in the development of IBIO-600, expanding iBio's clinical pipeline. The first participants in the trial are expected to be dosed during the second quarter of 2026.
Key Highlights
- iBio received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration for IBIO-600.
- Ethics approval was secured from a Human Research Ethics Committee, enabling the initiation of the trial.
- The clinical trial for IBIO-600 is a first-in-human study.
- The trial will be conducted in Australia.
- First participants are anticipated to be dosed in the second quarter of 2026.
Price Impact
More from IBIO